Multiplexed micronutrient, inflammation, and malarial antigenemia assessment using a plasma fractionation device

- 3 Eleanor Brindle¹, Lorraine Lillis², Rebecca Barney², Pooja Bansil², Francisco Arredondo³, Neal E. Craft⁴,
- 4 Eileen Murphy², David S. Boyle^{2*}
- ⁵ ¹ Center for Studies in Demography and Ecology, University of Washington, Seattle, WA, USA
- 6 ² PATH, Seattle, WA, USA
- 7 ³ Dept of Medicine, Duke University, Durham, NC, USA
- 8 ⁴ Craft Nutrition Consulting, Elm City, NC, USA
- 9 * To whom correspondence should be addressed: <u>dboyle@path.org</u>
- 10
- 11
- 12
- 13 NUMBER OF FIGURES: 4
- 14 NUMBER OF TABLES: 3
- 15 RUNNING TITLE: Analyses of plasma discs with a multiplexed quantitative immunoarray.

16 Abstract

17	Collecting, processing, and storing blood samples for future analysis of biomarkers can be challenging
18	when performed in resource limited environments. The preparation of dried blood spots (DBS) from
19	heel or finger stick collection of whole blood is a widely used and established method. DBS pose less risk
20	of infection from blood borne pathogens, do not require immediate specimen processing and tolerate a
21	wider range of storage temperatures, and are easier to ship. As such, DBS are commonly used in large-
22	scale surveys to assess infectious disease status and/or micronutrient status in vulnerable populations.
23	Recently, we reported that DBS can be used with a multiplexed immunoassay, the Q-plex™ Human
24	Micronutrient 7-plex Array (MN 7-plex). This tool can simultaneously quantify seven protein biomarkers
25	related to micronutrient deficiencies (iodine, iron and vitamin A), inflammation and malarial
26	antigenemia using plasma or serum. Serum ferritin, a key iron biomarker, cannot be measured from DBS
27	due to red blood cell (RBC) ferritin confounding the results. In this study, we demonstrate the
28	performance of a simple and rapid blood fractionation tool that passively separates serum from cellular
29	components via diffusion through a membrane into a plasma collection disc (PCD) to produce plasma
30	spots. We evaluated the concordance of MN 7-plex analyte concentrations from matched panels of
31	eighty-eight samples of PCD, DBS, and wet plasma prepared from anticoagulated venous whole blood.
32	The results show high correlation between eluates from PCD and DBS and wet plasma for each analyte.
33	Serum ferritin measures from the PCD eluates were highly correlated to wet plasma samples. This
34	suggests that surveillance for iron deficiency may be improved over the current methods restricted to
35	only measuring sTfR in DBS as when used in combination with the MN 7-plex, all seven biomarkers can
36	be simultaneously measured using PCDs.

37 Introduction

38	Micronutrient deficiency (MND) has been described as hidden hunger and an estimated 2 billion people
39	are affected globally [1] with lodine, Iron, and vitamin A representing three of the four primary MNDs of
40	global significance [2-4]. Sufficient concentrations of key micronutrients (MN) are required for normal
41	development of the fetus in utero, infants, and young children. MND can impair cognitive, immune,
42	ocular function and physical health and development. Fetuses, young children, and women of
43	reproductive age in are particularly at risk from MND and the global burden is greatest in low- and
44	middle-income countries (LMICs) that are the least equipped to routinely assess MN status [5].
45	There are low cost and effective solutions to mitigate the effects of MND including dietary initiatives,
46	fortification of common foodstuffs (e.g. salt or flour) or directly via supplementation [6-8]. The challenge
47	to nutrition programs and researchers in LMICs is to effectively perform population surveillance to
48	identify groups at most risk of MND before its effects manifest. Baseline data can identify the scale of
49	MND and groups at greatest risk so that effective interventions can be introduced. Interventions can
50	then be monitored via ongoing surveillance at scheduled intervals to establish their impact.
51	There is general consensus on a panel of blood-based biomarkers that are both informative on iodine,
52	iron or vitamin A status [9-13], and practical for use in population-level surveillance. These act as
53	surrogates to more direct MN measurement methods which involve challenging specimen collection
54	(e.g. bone marrow aspirates for iron measurement [14]) or require highly skilled users and complex
55	equipment (e.g. high pressure liquid chromatography for serum retinol analysis [15]). The blood
56	specimens for these tests can be collected by venipuncture or less invasive methods, such as finger- or
57	heel-stick capillary blood collection. Venous blood collection offers the advantage of much larger sample
58	volumes and reduced chance of bias resulting from the capillary blood collection technique (e.g. milking
59	fingers), but venous samples are more difficult to collect, particularly from children, and more

challenging to transport, process, and store [16]. Serum or plasma from whole blood must be rapidly 60 61 processed to avoid hemolysis and must be kept under cold chain to prevent decay of the biomarkers. A 62 perception of greater pain associated with venipuncture versus finger stick collection may also negatively influence participation in studies [17]. Blood and its derivatives pose biohazard risks, and 63 64 handling should only be performed by staff with certified training for blood borne pathogens [18]. 65 Therefore, the scaled collection of venous blood adds significant logistical, financial and technical 66 challenges particularity in low resource settings where the need for effective MND surveillance is 67 greatest.

68 The use of DBS as an alternative sample type meets many of the challenges presented with venous 69 whole blood. Blood collection of up to 250 µL from a heel or finger prick via sterile lancet can be 70 performed by less skilled users [28]. The blood is spotted on paper card and left to dry before being 71 stored in a sealed pouch with a desiccant to eliminate moisture. The preparation of a sample takes less 72 time, needs no ancillary equipment (e.g. centrifuge or refrigeration) and uses less materials and 73 consumables [16,19,20]. Once dried, the sample has greatly reduced biohazard risk during sample 74 handling and processing. DBS cards have the further advantages of being relatively small requiring 75 significantly less space in freezers during long-term storage, and as many biomarkers are stable in DBS at 76 a broader range of temperatures, they can be shipped using gel packs instead of dry ice, or even out of 77 cold chain [19,28-31].

A primary challenge in using DBS is that the sample quantity is limited, with a typical collection yielding
five spots of whole blood with approximately 50 µL each. Eluting DBS from filter paper results in dilution
of the specimen, so assays must be capable of quantifying low concentrations. We recently highlighted
that low concentration biomarkers such as thyroglobulin (Tg, µg/L) could be quantified from DBS eluates
using the Q-Plex[™] Human Micronutrient Array (Quansys Biosciences, Logan, Utah, USA) [21,22]. The Qplex is a multiplexed immunoarray that enables the simultaneous quantification of biomarkers to

deficiencies in iodine, iron, and vitamin A, in addition to inflammatory biomarkers and *Plasmodium falciparum*, from a single small volume of liquid serum or plasma [21].

While this evaluation found acceptable agreement between DBS and plasma for most analytes, using 86 87 DBS for iron deficiency assessment is challenging, because ferritin levels are grossly elevated by the co-88 elution of serum and red blood cell ferritin from lysed RBCs. Therefore, sTfR is the only iron biomarker 89 that can be measured from DBS [22,23]. While sTfR is one of the recommended biomarkers for iron 90 status assessment, we and other groups have reported challenges in harmonizing absolute sTfR values 91 derived from different immunoassay methods [19,21,24-26]. The ratio of sTfR to serum ferritin has been 92 found to be a better indicator of iron deficiency than either analyte alone [27]. As such, we hypothesize 93 that a parallel measurement of ferritin, inflammatory biomarkers and sTfR may give greater confidence 94 in establishing iron deficiency status. A variety of simple devices have been described or developed to 95 passively fractionate plasma from whole blood, primarily to enable more accurate determination of viral 96 load testing of people living with HIV [28,29].

In this manuscript we describe an evaluation of use of the Q-plex[™] micronutrient 7-Plex assay (hereafter MN 7-plex) with matched sets of plasma, eluates of DBS, and eluates from a prototype of the plasma collection disc (PCD), a passive blood fractionation device (a commercial version, the DriVive is now offered by ViveBio LLC, Alpharetta, GA, USA) [30]. In particular, we evaluate whether the PCD allows reliable measurement of ferritin using a method with the same logistical advantages as DBS. We also evaluate performance of the MN 7-plex using DBS and plasma prepared from heparinized whole blood samples as opposed to EDTA blood used in an earlier DBS study [22].

104 Materials and methods

105 Collection of whole blood specimens.

- 106 Specimens of ~8 mLs of human whole blood were procured from a commercial vendor, BioIVT
- 107 (Westbury, New York). The WIRB protocol number for the collection of 80 blood samples was 20161665
- 108 and all specimens were obtained only after signed consent by each participant. The PATH Office of
- 109 Research Affairs deemed the use of these samples to be non-human subjects research.
- ¹¹⁰ Preparation of DBS, PCD and plasma panels

111 A panel of 80 heparinized anticoagulated whole blood samples (40 adult male, 40 adult female) was 112 procured. The whole blood was delivered to the PATH laboratory the next day, and processed upon 113 receipt to prepare three sample types (DBS, PCD, and plasma) within 24 hours of blood collection. Upon 114 arrival in the laboratory, blood was continuously rotated at 4 °C before processing to ensure it remained 115 thoroughly mixed. Matched sets of plasma, DBS and PCD were prepared in triplicate from the eighty 116 blood specimens and the complete panels were measured in three different laboratories for α -acid 117 glycoprotein (AGP), C-reactive protein (CRP), Ferritin, histidine rich protein 2 (HRP2), retinol binding 118 protein 4 (RBP4), soluble transferrin receptor (sTfR), and thyroglobulin (Tg) using the MN 7-plex. 119 Because the blood panel was derived from US donors, it was not expected to include malarial 120 parasitemia or a high prevalence of inflammation or iron deficiency [22]. Thus, twenty whole blood 121 samples were randomly chosen from the set and a portion of the whole blood was spiked with calibrator 122 solutions provided by Quansys to simulate samples positive for HRP2 and with elevated AGP, CRP, or 123 sTfR levels. Each contrived sample was prepared by transferring 2 mL of whole blood to a new tube, 124 adding spike solutions and gently mixing by rotating tubes at 4 °C for at least 5 minutes (see Table 1).

125 The resulting samples (Sample numbers 81 – 100) were then processed for DBS and PCD as described

126 below (Figure 1).

127

	Spike	Analyte	Spike Level	# samples	Spiking solution added (µL)	Total Volume	Expected added concentration
	1	HRP2	Very High	F	11 7	70	3.40 μg/L
1	T	sTfR	High	Э	11.7	70	160 mg/L
	2	HRP2	High	F	3.9	20	0.843 μg/L
	Z	sTfR	Mid	5		50	13 mg/L
	3	HRP2	Mid	F	10.0	110	0.286 μg/L
		CRP	High	С	18.8	110	120 mg/L
	Λ	HRP2	Low	E	144.9	750	0.045 μg/L
	4	AGP	High	5	144.8	750	2.0 g/L

Table 1. Contrived blood samples spiked with a range of elevated levels of AGP, CRP, HRP2 and sTfR.

129

130 **Figure 1.** Sample panels and experiment design

131

132

133

134 DBS were prepared from the 80 whole blood specimens and 20 spiked whole blood specimens by

dropping 70 μL of whole blood onto Whatman 903 cards (n=100). The cards were stored overnight to

dry at room temperature and then individually stored at -80°C in sealed plastic pouches with desiccant

- 137 packets.
- 138 Prototype PCDs were assembled from parts supplied by the manufacturer for use in these experiments.
- 139 To produce the PCD, each absorbent plasma collection disc was loaded onto a custom-made manifold
- and covered by a separation membrane (Figure 2). A volume of 35 µL of whole blood was added to each
- 141 PCD membrane using a wide-bore pipet tip. After approximately 90 minutes, the PCD membranes
- 142 containing the RBCs and other cellular components were removed and discarded. The PCDs containing

143	the adsorbed plasma were then removed from the manifold and stored in zipped plastic bags with
144	desiccant at -80 °C. Samples 63-80 were omitted from this portion of the testing for lack of PCD units;
145	the resulting final panel included PCDs from 62 unadulterated donor specimens and 20 PCDs from
146	spiked specimens (n=82). Significant hemolysis was noted on one PCD (ID 12), and corresponding DBS
147	spots appeared very pale. Some slight hemolysis above background was observed on PCDs for 14
148	samples. Remaining whole blood was then processed to collect plasma fractions (n = 100) as previously
149	described [24]. These plasma fractions were aliquoted into cryovials and stored at -80°C until use. The
150	PCDs were eluted at PATH. The eluted material from the triplicate samples was pooled, mixed and then
151	aliquots of approximately 180 μL was sent to each laboratory on dry ice (see next section), along with
152	matched DBS cards and plasma samples.
153	
154	Figure 2. The plasma collection disc in operation. Left to right, the PCD with the the filter disc placed on
154 155	Figure 2. The plasma collection disc in operation. Left to right, the PCD with the the filter disc placed on the manifold prior to whole blood being added, addition of 35 μ L of whole blood to each disc, the discs
154 155 156	Figure 2. The plasma collection disc in operation. Left to right, the PCD with the the filter disc placed on the manifold prior to whole blood being added, addition of 35 μ L of whole blood to each disc, the discs afterblood has been absorebed and finally the plasma collection disc exposed after the whole blood
154 155 156 157	Figure 2. The plasma collection disc in operation. Left to right, the PCD with the the filter disc placed on the manifold prior to whole blood being added, addition of 35μ L of whole blood to each disc, the discs afterblood has been absorebed and finally the plasma collection disc exposed after the whole blood treated filter has been removed. The disc is removed with sterile forceps and is ready for use or can be
154 155 156 157 158	Figure 2. The plasma collection disc in operation. Left to right, the PCD with the the filter disc placed on the manifold prior to whole blood being added, addition of 35 µL of whole blood to each disc, the discs afterblood has been absorebed and finally the plasma collection disc exposed after the whole blood treated filter has been removed. The disc is removed with sterile forceps and is ready for use or can be stored until required.
154 155 156 157 158 159	Figure 2. The plasma collection disc in operation. Left to right, the PCD with the the filter disc placed on the manifold prior to whole blood being added, addition of 35 µL of whole blood to each disc, the discs afterblood has been absorebed and finally the plasma collection disc exposed after the whole blood treated filter has been removed. The disc is removed with sterile forceps and is ready for use or can be stored until required.
154 155 156 157 158 159 160	Figure 2. The plasma collection disc in operation. Left to right, the PCD with the the filter disc placed on the manifold prior to whole blood being added, addition of 35 µL of whole blood to each disc, the discs afterblood has been absorebed and finally the plasma collection disc exposed after the whole blood treated filter has been removed. The disc is removed with sterile forceps and is ready for use or can be stored until required.
154 155 156 157 158 159 160 161	Figure 2. The plasma collection disc in operation. Left to right, the PCD with the the filter disc placed on the manifold prior to whole blood being added, addition of 35 μ L of whole blood to each disc, the discs afterblood has been absorebed and finally the plasma collection disc exposed after the whole blood treated filter has been removed. The disc is removed with sterile forceps and is ready for use or can be stored until required.
154 155 156 157 158 159 160 161 162	Figure 2. The plasma collection disc in operation. Left to right, the PCD with the the filter disc placed on the manifold prior to whole blood being added, addition of 35 µL of whole blood to each disc, the discs afterblood has been absorebed and finally the plasma collection disc exposed after the whole blood treated filter has been removed. The disc is removed with sterile forceps and is ready for use or can be stored until required.

164 with the Q-plex assay. DBS processing was carried out in each laboratory the day before assay. Two 6

165 mm punches, equivalent to approximately 6 μ L of serum [31], were placed in 244 μ L sample diluent

(approx. 1:20 dilution) and left overnight at 4°C. Samples were then shaken at 200 rpm on a microplate 166 167 shaker for one hour at room temperature before using. PCD processing occurred in one laboratory, with 168 aliquots of elutes then shared with all 3 laboratories. Each PCD with an estimated equivalent of 169 approximately 8 to 10 µL plasma per PCD was placed in a microcentrifuge tube separation column with a 170 paper filter membrane (Pierce Spin Cups, ThermoFisher Scientific, Waltham, MA, USA) and 200 µL of 171 diluent was added to each PCD, resulting in a dilution of approximately 1 in 20. Samples were incubated at room temperature for two hours before being centrifuged at 12,500 rpm for 15 minutes. Three PCDs 172 173 per sample were eluted following this procedure, and recovered eluates were pooled for each sample, 174 mixed and aliquoted in \sim 180 μ L volumes for transfer to the laboratories for testing.

175 Human Micronutrient (7-Plex) assay procedure

The MN 7-plex protocol instructs the user to prepare all samples, negative control and calibrator dilutions in sample diluent containing reconstituted competitor. Because the competitor may degrade during the incubation time required for DBS or PCD elution, the standard protocol was modified to add competitor to the mix after sample elution. These protocol alterations were also used for wet plasma specimens included in these analyses.

181 Competitor was reconstituted in one tenth of the volume of diluent suggested in the MN 7-plex manual 182 to produce a 10X competitor stock and 144 μ L of eluate from either DBS or PCD was mixed with 16 μ L of 183 10X assay competitor mix resulting in 1X competitor in a final sample dilution of approximately 1 in 22. 184 Similarly, kit diluent without competitor was used to dilute wet plasma specimens to 1 in 20, and to 185 reconstitute the calibrator provided with the kit and prepare the standard curve; 10X competitor mix 186 was added to prepared solutions as 10% of the final volume. Then 50 µL of each solution was added into 187 the test wells of the Q-plex assay in duplicate, and the remainder of the protocol was carried out as 188 directed in the kit manual.

189 After addition of the standards and samples, each plate was incubated at room temperature for two 190 hours with shaking at 500 RPM using a flatbed shaker (Titertek Berthold, Huntsville, Alabama, USA). All 191 reactions were aspirated and washed 3 times with 400 µL of wash buffer supplied with the MN 7-plex kit 192 using an automatic plate washer. Next, 50 µL of detection mix was added to each well and the plate was 193 then incubated with shaking at 500 RPM for 1 hour and washed one more time as described above. 50 194 µL streptavidin horseradish peroxidase solution was added to each well and plates were incubated with 195 shaking for 20 minutes. Following another wash as described above, the chemiluminescent substrate 196 parts A and B were mixed in equal volumes and 50 µL of the mixture was then added to each well. 197 Each plate was then imaged at 270 seconds of exposure time using a Quansys Q-View™ Imager LS 198 (Quansys Biosciences). Q-View[™] Software (Quansys Biosciences) was used to overlay a plate map onto 199 the locations of analyte spots in each well and to measure the chemiluminescent signal from each spot 200 in units of pixel intensity. The software applies the calibrator concentration values to the pixel intensities 201 for each spot in the standard curve wells and fits 5 parameter logistic calibration curves for each analyte. 202 The pixel intensities of the spots in each test well are then used to interpolate the concentration of each 203 analyte relative to its calibrator curve. Once the plate image is overlaid with the analysis grid, all of the 204 curve fitting and data reduction steps are automatically applied via the software. The upper and lower 205 limits of quantification determined by Quansys for each kit lot were applied to exclude values beyond 206 the assay concentration ranges. All values were adjusted for dilutions.

207

208 Statistical methods

Reproducibility across the three laboratories was determined using coefficient of variation (CV, mean
divided by standard deviation) of the three measures for each sample type. The CVs were also used to
assess the inter-assay and inter-laboratory variation. Concordance between AGP, CRP, ferritin, HRP2,

212	RBP4, sTfR, and Tg results in plasma with both DBS (100 pairs) and PCD (82pairs) was evaluated using
213	scatter plots, Lin's concordance correlation coefficient and Spearman's correlation coefficient [32].
214	Agreement in absolute value was evaluated by calculating recovery of plasma values from DBS or PCD
215	(DBS or PCD concentration/plasma concentration, expressed as a percentage) and using Bland Altman
216	plots of the average concentration plotted against the percentage difference in concentrations of each
217	analyte in plasma/DBS or PCD sample pair. Statistical analyses were conducted using Stata 15.1
218	(StataCorp, College Station, TX, USA). All of the data generated in this study can be publicly accessed at
219	Dataverse (https://doi.org/10.7910/DVN/VY3MDB).

220

221 Results

222	Summary statistics for each analyte and sample type and CVs for the measures across the three
223	participating laboratories are shown in Table 1. The CVs for plasma and DBS were similar, with higher
224	CVs in the PCDs for most analytes. CVs were extremely high for sTfR, reflecting a large discrepancy
225	between values from one laboratory as compared to those from the other two. Excluding those results
226	reduced CVs, but they remained over 30% for sTfR. CVs were also high for HRP2, regardless of sample
227	type, because of the semi-quantitative nature of the assay. Most specimens in the panel contained no
228	detectable HRP2; spiked samples contained high values near or above the upper limit of detection for
229	the assay. For ferritin, the DBS samples saturated the assay and were at the upper limit of detection,
230	leading to high CVs. This was expected given the presence of red blood cell (RBC) associated ferritin
231	present in this sample type.

Table 2. Summary statistics and cross-laboratory coefficients of variation (CV) for plasma, DBS and PCD. Spiked samples contain added AGP, CRP,

HRP2, and/or sTfR as shown in Table 1. The concentrations are mean values from testing at PATH, UW, and Eurofins. sTfR results are given with

and without data from the Eurofins lab. Average CV is the average of the individual sample CVs calculated from results across the 3 laboratories.

Abbreviations: AGP, α-1-acid glycoprotein; CRP, C-reactive protein; CV, coefficient of variation; DBS, dried blood spots; N, number; PCD, plasma

236 collection disc; RBP4, retinol-binding protein 4; SD, standard deviation; sTfR, soluble transferrin receptor; Tg, thyroglobulin.

		Plasma		DBS			PCD			
		N	Mean (SD)	Average CV	N	Mean (SD)	Average CV	Ν	Mean (SD)	Average CV
	All	100	1.1 (0.6)	10.9%	100	1.2 (0.6)	10.8%	82	0.6 (0.2)	8.7%
AGP (g/L)	Unspiked	80	1.0 (0.2)	11.5%	80	1.1 (0.3)	11.3%	62	0.5 (0.2)	7.0%
	Spiked	20	1.55 (1.2)	8.7%	20	1.7 (1.1)	9.0%	20	0.7 (0.4)	14.1%
	All	92	7.44 (12.3)	19.1%	89	5.5 (8.6)	16.0%	73	2.8 (4.1)	18.3%
CRP (mg/L)	Unspiked	73	4.93 (5.4)	20.6%	70	3.6 (4.1)	18.5%	54	1.9 (2.0)	20.5%
	Spiked	19	17.08 (22.9)	13.4%	19	12.2 (15.3)	7.2%	19	5.3 (7.0)	13.2%
	All	99	42.9 (40.6)	17.7%	100	178.8 (114.1)	11.6%	75	18.4 (16.0)	23.6%
Ferritin	Unspiked	79	43.6 (43.5)	15.6%	80	178.9 (115.2)	12.0%	56	19.0 (17.3)	26.5%
(µ6/ ⊑/	Spiked	20	39.9 (27.2)	25.8%	20	178.3 (112.4)	10.2%	19	16.7 (11.3)	16.1%
HRP2 (µg/L)	All	26	3.59 (4.8)	18.6%	100	0.79 (2.1)	60.7%	49	0.9 (1.5)	52.2%
(semi-	Unspiked	6	0.17 (0.1)	12.2%	80	0.10 (0.0)	62.2%	29	0.2 (0.0)	92.6%
quantitative)	Spiked	20	4.61 (5.1)	19.0%	20	3.55 (3.5)	59.4%	20	1.9 (2.0)	45.8%
2224	All	100	1.67 (0.6)	12.2%	100	1.20 (0.3)	9.2%	82	0.6 (0.2)	10.3%
RBP4	Unspiked	80	1.65 (0.6)	12.7%	80	1.16 (0.3)	10.4%	62	0.6 (0.2)	9.5%
(μποι/ε)	Spiked	20	1.74 (0.6)	10.5%	20	1.34 (0.4)	4.4%	20	0.7 (0.2)	12.6%
	All	100	43.9 (38.6)	35.3%	100	80.9 (40.2)	9.2%	82	74.2 (38.2)	91.9%
sTfR (mg/L)	Unspiked	80	40.8 (38.2)	33.5%	80	79.3 (41.6)	9.5%	62	69.0 (38.0)	89.5%
	Spiked	20	56.1 (38.8)	42.4%	20	87.2 (34.2)	8.1%	20	90.2 (35.1)	99.2%
sTfR (mg/L),	All	100	48.6 (41.3)	35.9%	100	82.5 (42.0)	9.9%	81	35.2 (19.8)	34.3%
excluding	Unspiked	80	44.7 (39.7)	34.1%	80	80.8 (43.8)	10.5%	61	33.6 (20.1)	34.6%
Eurofins	Spiked	20	64.0 (45.1)	43.0%	20	89.0 (34.3)	7.4%	20	39.9 (18.7)	33.2%
	All	98	23.8 (22.1)	12.2%	99	21.1 (21.7)	8.7%	81	12.4 (13.3)	27.5%
Tg (μg/L)	Unspiked	78	22.6 (20.5)	13.1%	79	20.0 (19.6)	9.2%	61	11.2 (10.7)	28.0%
	Spiked	20	28.4 (27.7)	8.9%	20	25.5 (28.9)	6.7%	20	16.1 (19.2)	26.2%

238	Spearman correlations between plasma and DBS and between plasma and PCDs are shown in Table 3.
239	As with Table 2results are shown including and excluding the highly discrepant sTfR data. The Spearman
240	correlation coefficients (Spearman's rho) between the plasma and the DBS samples were generally high
241	with all being 0.93 or higher with the exception of ferritin. These results closely match previous
242	observations using DBS samples with the 7-plex assay [22]. As expected, the correlation between plasma
243	ferritin and DBS ferritin was low (0.640) as DBS eluates contain a mixture of ferritin from serum and
244	from red blood cells. The correlation of plasma ferritin to PCD ferritin was 0.925, highlighting the
245	potential advantage of PCDs for ferritin measurement in dry samples. The correlation for RBP4 from PCD
246	was lower than from DBS (0.993 versus 0.840). The sTfR correlation for all data was poor (0.545) but was
247	significantly improved when the aberrant data from one site are excluded (0.858).
248	
249	Table 3. The comparison of results for plasma, DBS and PCD eluates using Spearman correlation and
250	recovery of expected plasma values. For the PCD, the adjusted values reflect an estimate of 5 μL of
251	plasma from each disc instead of 10 μ L of plasma as originally estimated. For sTfR, results are shown
252	with and without data from Eurofins. Abbreviations: AGP, α -1-acid glycoprotein; CRP, C-reactive protein;
253	DBS, dried blood spots; EF, Eurofins ; N, number; PCD plasma collection disc; RBP4, retinol-binding

protein 4; SD, standard deviation; sTfR, soluble transferrin receptor; Tg, thyroglobulin. Rho, rank-ordercorrelation.

	AGP	CRP	Ferritin	HRP2	RBP4	sTfR	sTfR excl. EF	Tg
DBS								
N (pairs)	100	89	99	26	100	100	100	98
Spearman's Rho	0.975	0.988	0.640	0.977	0.993	0.930	0.947	0.995
Recovery, mean (SD%)	116 (15)	71 (14)	570 (400)	98 (55)	74 (9)	234 (80)	215 (76)	89 (11)
PCD								
N (pairs)	82	71	75	21	82	82	81	81
Spearman's Rho	0.954	0.981	0.925	0.919	0.840	0.583	0.858	0.977
Recovery mean (SD%)	51 (11)	39 (18)	45 (15)	52 (33)	37 (8)	218 (110)	88 (35)	51 (12)
Adj. Spearman's Rho	0.835	0.965	0.848	0.914	0.760	0.798	0.855	0.964
Adj. Recovery mean (SD) %	101 (21)	79 (36)	90 (29)	103 (66)	73 (16)	436 (220)	176 (69)	102 (24)

256

257	The mean recovery compares concentrations of each analyte in DBS or PCDs relative to plasma
258	concentrations (Table 3). Concentrations of all, spiked, and unspiked, samples were similar for plasma
259	and DBS, but PCD values were approximately half the values measured in plasma. For AGP, HRP2 and Tg,
260	values recovered from DBS were within one standard deviation of 100% of the plasma values, while CRP
261	and RBP4 recoveries from DBS were lower at 71% and 74%, respectively. For DBS versus plasma sTfR,
262	the recovery rates from DBS were very high at 234%. Excluding results from one of the three sites only
263	marginally improved DBS recovery relative to plasma (215%) The impact of the discrepant sTfR data
264	were more pronounced for the recovery from PCDs relative to plasma; including all data, the sTfR
265	recovered from PCDs was 436% ±220% relative to plasma, but when sTfR results from the Eurofins lab
266	are excluded, the PCD values were $176\% \pm 69\%$ of plasma.
267	Original concentration estimates for the PCD eluates used the assumption that each disc contained the
268	equivalent of approximately 10 μ L of plasma, resulting in a dilution of 1 in 22 when the disc was eluted.
269	Recovery results shown in Table 3 suggest that the volume of plasma recovered from the disc is
270	approximately 50% of the original estimate, giving an eluate dilution of 1 in 44. Adjusting the PCD results
271	to account for the new plasma volume equivalent improved agreement with plasma values in terms of
272	absolute values, but had minimal impacts on correlation (Table 3, Figure 3Aand 3B).
273	

Figure 3A. Lin's CCC plots comparing the analyte measurements in paired wet plasma (x-axes) and DBS
samples (y-axes).

276

277

278

Figure 3B, Lin's CCC plots comparing the analyte measurements in paired wet plasma (x-axes) and the
 adjusted PCD (, y-axes). AGP, α-1-acid glycoprotein; CRP, C-reactive protein; FER, ferritin; HRP2, histidine
 rich protein 2; RBP4, retinol binding protein 4; sTfR, soluble transferrin receptor; Tg, thyroglobulin; DBS,
 dried blood spot.

283

284 To complete our comparative analysis we also assessed the correlation of the DBS and the adjusted PCD 285 samples to the plasma samples using scatter plots with linear regression lines (Figures 3A and 3B) and 286 their agreement using Bland Altman plots (Figures 4A and 4B). We used Lin's concordance correlation 287 coefficient (CCC) to create scatter plots to compare the measurements [33]. AGP and Tg were both very 288 close to the line of perfect concordance and sTfR is correlative though the reduced major axis is 289 consistently greater than the line of perfect correlation. HRP2, CRP and RBP4 are less concordant while 290 bias increases showing greater variance at the higher analyte concentrations. The plot for ferritin shows 291 the lowest correlation as is expected since DBS samples have ferritin contributed from RBCs. With the 292 exception of the sTfR plot, all other DBS analytes tended to be lower than plasma values. For most 293 analytes, the correlation of adjusted PCD and plasma was similar to that of DBS and plasma. 294 Figure 4A. Plots of the difference in results derived from wet plasma versus dry samples types measured 295 using the 7-plex assay. Average of the wet plasma and dry sample type (x-axes) are plotted against the 296 difference between measurements from the 7-Plex assay for paired wet plasma and dry sample types (y-297 axes). Fig 3A, the plasma versus DBS samples; Figure 4B. the plasma versus the adjusted PCD. Horizontal 298 lines indicate line of perfect agreement (green), mean (purple), and ± 2standard deviations of the 299 difference (red). AGP, α -1-acid glycoprotein; CRP, C-reactive protein; FER, ferritin; HRP2, histidine rich 300 protein 2; RBP4, retinol binding protein 4; sTfR, soluble transferrin receptor; Tg, thyroglobulin; DBS, 301 dried blood spot.

302 Discussion

303	Correlation, concordance plots, and Bland Altman plots suggest that plasma and PCDs show good
304	agreement for AGP, CRP, ferritin, HRP2, RBP, and Tg, but not sTfR. The sTfR results show gross variance
305	between the absolute values for all three sample types (see Table 3). The sTfR assay remained the least
306	concordant, especially at the higher values. The increasing bias was again evident with the samples
307	having more variance at the higher concentrations of analyte. Most of the plots (Fgirues 3 and 4)
308	showed a slight positive bias at the upper dynamic ranges of each assay. With the exception of sTfR and
309	marginally HRP2, the trend was that the values for the adjusted PCD were below those for plasma. As
310	expected, the agreement of PCD data for the ferritin data sets was signifcantly better than with the DBS
311	samples. The primary advantage of PCDs over DBS is the improved correlation of ferritin results from
312	plasma and dry blood with the removal of RBCs from the samples.
313	One significant limitation that was identified was uncertainty about the volume of plasma captured in
314	each disc; this needs to be fully validated. We had estimated that each PSC absorbed a volume of 10 μL
315	plasma per disc but it was evident from the mean recoveries that the discs either contained ~50% less
316	plasma or that some material was bound or retained within the disc. Therefore a rigorous assessment of
317	the volumetric capacity of the PCD is warranted, essentially mimicking the effort to assess the volume of
318	material retained in DBS relative to sampling volumes [20]. Earlier work on dried serum spots spotted
319	precise volumes of serum onto filter paper and so the exact volume of material was known, simplifying
320	the harmonization of data. We suspect that while processing PCD with whole blood under vacuum,
321	some of the serum/plasma was drawn from the disc and lost, resulting in smaller sample volume being
322	retained in the dead space of the disc pores. It is also possible that DriVive production version of the
323	PCDs will retain plasma more efficiently than did our prototype versions assembled in the lab.

In this work, the samples were eluted from the PCDs soon after preparation and stored at low temperatures to preserve the integrity of the samples before testing. Future tests will be required to understand the stability of the biomarkers in dried PCDs as their intended use will include population based micronutrient surveys in austere settings where access to refrigeration will be limited or absent, so adequate stability of the samples out of cold chain is essential. Dried serum spots have been shown to be stable for at least two weeks but in this case the precise volume of serum per serum spot was known and so comparative analyses is easier [34].

The sTfR data is a concern in that the original DBS and PCD samples had mean recoveries of over 200%,

due in part to elevated sTfR from one partner laboratory. The source of this discrepancy could not be

identified; all laboratories used the same lot of plates and the other 6 assays in the multiplex gave mean

recoveries similar to the paired data from other laboratories meaning the issue was specific to the sTfR

assay performed in the one laboratory. When this data was removed to create the adjusted datasets,

the mean recovery was not significantly changed with DBS samples. With the exclusive PSC data the sTfR

recovery did drop significantly but when the adjustment for volumetric bias was applied the mean

recovery was still high at 176 mg/mL. Since we conducted this evaluation, Quansys have released a new

version of MN 7-plex array in which they claim the sTfR assay has been completely redeveloped with

new antibodies. Quansys reports that the new assay has significantly better performance when assessed

341 with the Vital EQA panel provided by the US CDC [35]. We are currently assessing the performance of

342 the previous and new version of the array to independently confirm that the discordance and elevated

343 recoveries observed with sTfR are significantly reduced.

From this study it appears that the PCD has potential to be an effective tool for the rapid instrument free fractionation of plasma from whole blood samples. Previously, we had shown that DBS could be used as a specimen type for use with the MN-7 plex assay, but DBS are limited to only 6 of the biomarkers (AGP, CRP, HRP2, RBP4, sTfR and Tg) [22]. The inability to accurately measure serum ferritin

348	is a significant drawback to using DBS if measuring iron levels is a primary goal, as sTfR measurement
349	alone is insufficient for accurate determination of iron deficiency. Here we have shown that ferritin can
350	be measured from the PCD and that the values derived were correlative to and in agreement with
351	plasma samples and with other previously reported work [34,36]. In this experiment, we were able to
352	evaluate HRP2 as an indicator of <i>Plasmodium falciparum</i> antigenemia via spiking with the antigen, thus
353	adding an assessment missing from our previous test of the use of DBS with the MN 7-plex. HRP2 was
354	recovered well from both DBS and the PCD eluates, suggesting that the malarial antigen assay is
355	functional with either DBS or PCD samples. Thus, with the addition of this evidence about the
356	performance of HRP2 and ferritin measures in samples collected using PCDs, our results suggest that all
357	seven analytes in the MN 7-plex can be measured reliably using a dry sample collection method that
358	eliminates the need for sample processing in the field and minimizes cold chain requirements.
359	

360 Acknowledgments

We greatly appreciate the collaborative support of ViveBio LLC in supplying prototype PCD devices and
their expert technical input. We would like to thank Dr Emily Smith (The George Washington University)
and Dr Ken Brown (U.C. Davis) for their critical thinking and advice. We would also like to thank Ms.
Olivia Halas for her administrative support in preparing and reviewing the manuscript for submission.

366

367

368 References

369	1.	de Benoist B., Mclean E., Egli I., and Cogswell M. Worldwide Prevalence of Anaemia 1993-2005:
370		WHO Global Database on Anaemia. Geneva: World Health Organization; 2008.
371	2.	Lynch S, Pfeiffer CM, Georgieff MK, Brittenham G, Fairweather-Tait S, Hurrell RF, et al.
372		Biomarkers of Nutrition for Development (BOND)-Iron Review. J Nutr. 2018;148: 1001S-1067S.
373	3.	Rohner F, Zimmermann M, Jooste P, Pandav C, Caldwell K, Raghavan R, et al. Biomarkers of
374		nutrition for development-iodine review. J Nutr. 2014;144: 1322S-1342S.
375	4.	Tanumihardjo SA, Russell RM, Stephensen CB, Gannon BM, Craft NE, Haskell MJ, et al.
376		Biomarkers of Nutrition for Development (BOND)-Vitamin A Review. J Nutr. 2016;146: 1816S-
377		18485.
378	5.	Bailey RL, West KP, Jr., Black RE. The epidemiology of global micronutrient deficiencies. Ann Nutr
379		Metab. 2015;66 Suppl 2: 22-33.
380	6.	Cichon B, Fabiansen C, Iuel-Brockdorf AS, Yameogo CW, Ritz C, Christensen VB, et al. Impact of
381		food supplements on hemoglobin, iron status, and inflammation in children with moderate
382		acute malnutrition: a 2 x 2 x 3 factorial randomized trial in Burkina Faso. Am J Clin Nutr.
383		2018;107: 278-286.
384	7.	Wirth JP, Petry N, Tanumihardjo SA, Rogers LM, McLean E, Greig A, et al. Vitamin A
385		Supplementation Programs and Country-Level Evidence of Vitamin A Deficiency. Nutrients.
386		2017;9:
387	8.	Abe SK, Balogun OO, Ota E, Takahashi K, Mori R. Supplementation with multiple micronutrients
388		for breastfeeding women for improving outcomes for the mother and baby. Cochrane Database
389		Syst Rev. 2016;2: CD010647.

390	9.	Almekinder J, Manda W, Soko D, Lan Y, Hoover DR, Semba RD. Evaluation of plasma retinol-
391		binding protein as a surrogate measure for plasma retinol concentrations. Scand J Clin Lab
392		Invest. 2000;60: 199-203.
393	10.	Beguin Y. Soluble transferrin receptor for the evaluation of erythropoiesis and iron status. Clin
394		Chim Acta. 2003;329: 9-22.
395	11.	Guagnozzi D, Severi C, Ialongo P, Viscido A, Patrizi F, Testino G, et al. Ferritin as a simple
396		indicator of iron deficiency in anemic IBD patients. Inflamm Bowel Dis. 2006;12: 150-151.
397	12.	Kifude CM, Rajasekariah HG, Sullivan DJ, Jr., Stewart VA, Angov E, Martin SK, et al. Enzyme-
398		linked immunosorbent assay for detection of Plasmodium falciparum histidine-rich protein 2 in
399		blood, plasma, and serum. Clin Vaccine Immunol. 2008;15: 1012-1018.
400	13.	Stinca S, Andersson M, Weibel S, Herter-Aeberli I, Fingerhut R, Gowachirapant S, et al. Dried
401		Blood Spot Thyroglobulin as a Biomarker of Iodine Status in Pregnant Women. J Clin Endocrinol
402		Metab. 2017;102: 23-32.
403	14.	Gale E, Torrance J, Bothwell T. The quantitative estimation of total iron stores in human bone
404		marrow. J Clin Invest. 1963;42: 1076-1082.
405	15.	De Ruyter MG, De Leenheer AP. Determination of serum retinol (vitamin A) by high-speed liquid
406		chromatography. Clin Chem. 1976;22: 1593-1595.
	16	Ostler MW. Porter JH. Buxton OM. Dried blood spot collection of health biomarkers to maximize
407	10.	

409	17.	Daneau G, Gous N, Scott L, Potgieter J, Kestens L, Stevens W. Human Immunodeficiency Virus
410		(HIV)-Infected Patients Accept Finger Stick Blood Collection for Point-Of-Care CD4 Testing. PLoS
411		One. 2016;11: e0161891.
412	18.	Bahadori M, Sadigh G. Occupational exposure to blood and body fluids. Int J Occup Environ Med.
413		2010;1: 1-10.
414	19.	Brindle E, O'Connor KA, Garret DA. Applications of Dried Blood Spots in General Human Health
415		Studies. In: Li W, Lees MS, editors. Dried Blood Spots. New York: Wiley.
416	20.	Mei JV, Alexander JR, Adam BW, Hannon WH. Use of filter paper for the collection and analysis
417		of human whole blood specimens. J Nutr. 2001;131: 1631S-1636S.
418	21.	Brindle E, Lillis L, Barney R, Hess SY, Wessells KR, Ouedraogo CT, et al. Simultaneous assessment
419		of iodine, iron, vitamin A, malarial antigenemia, and inflammation status biomarkers via a
420		multiplex immunoassay method on a population of pregnant women from Niger. PLoS One.
421		2017;12: e0185868.
422	22.	Brindle E, Lillis L, Barney R, Bansil P, Lyman C, Boyle DS. Measurement of micronutrient
423		deficiency associated biomarkers in dried blood spots using a multiplexed immunoarray. PLoS
424		One. 2019;14: e0210212.
425	23.	Cook JD, Flowers CH, Skikne BS. An assessment of dried blood-spot technology for identifying
426		iron deficiency. Blood. 1998;92: 1807-1813.
427	24.	Brindle E, Stevens D, Crudder C, Levin CE, Garrett D, Lyman C, et al. A multiplex immunoassay
428		method for simultaneous quantification of iron, vitamin A and inflammation status markers.
429		PLoS One. 2014;9: e115164.

430	25.	Thorpe SJ, Walker D, Arosio P, Heath A, Cook JD, Worwood M. International collaborative study
431		to evaluate a recombinant L ferritin preparation as an International Standard. Clin Chem.
432		1997;43: 1582-1587.
433	26.	Wians FH, Jr., Urban JE, Kroft SH, Keffer JH. Soluble transferrin receptor (sTfR) concentration
434		quantified using two sTfR kits: analytical and clinical performance characteristics. Clin Chim Acta.
435		2001;303: 75-81.
436	27.	Lynch S, Pfeiffer CM, Georgieff MK, Brittenham G, Fairweather-Tait S, Hurrell RF, et al.
437		Biomarkers of Nutrition for Development (BOND)-Iron Review. J Nutr. 2018;148: 1001S-1067S.
438	28.	Mukherjee S, Kang TG, Chen Y, Kim S. Plasma separation from blood: the 'lab-on-a-chip'
439		approach. Crit Rev Biomed Eng. 2009;37: 517-529.
440	29.	Wang S, Sarenac D, Chen MH, Huang SH, Giguel FF, Kuritzkes DR, et al. Simple filter microchip
441		for rapid separation of plasma and viruses from whole blood. Int J Nanomedicine. 2012;7: 5019-
442		5028.
443	30.	Arredondo FX, Craft NE, Fleshman MK. Screening of Dried Matrix Spot Collection Devices to be
444		Used for Nutritional Biomarker Analysis. The FASEB Journal. 2017;31_Supplment. Experimental
445		Biology 2017 Meeting Abstracts.:
446	31.	Hall EM, Flores SR, De J, V. Influence of Hematocrit and Total-Spot Volume on Performance
447		Characteristics of Dried Blood Spots for Newborn Screening. Int J Neonatal Screen. 2015;1: 69-
448		78.
449	32.	Lin L, Hedayat AS, Wu W. A unified approach for assessing agreement for continuous and
450		categorical data. J Biopharm Stat. 2007;17: 629-652.

- 451 33. Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics. 1989;45:
- 452 255-268.
- 453 34. Ahluwalia N, de SA, Atukorala S, Weaver V, Molls R. Ferritin concentrations in dried serum spots
- 454 from capillary and venous blood in children in Sri Lanka: a validation study. Am J Clin Nutr.
- 455 2002;75: 289-294.
- 456 35. Vitamin A Laboratory External Quality Assessment (VITAL-EQA) Program. US Centers for
- 457 Disease Control and Prevention . 2021. 10-28-0201.
- 458 <u>https://www.cdc.gov/nceh/dls/vitaleqa.html</u>
- 459 36. Ahluwalia N, Lonnerdal B, Lorenz SG, Allen LH. Spot ferritin assay for serum samples dried on
- 460 filter paper. Am J Clin Nutr. 1998;67: 88-92.











